IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-22351-5.html
   My bibliography  Save this article

Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany

Author

Listed:
  • N. Ahmad Aziz

    (German Center for Neurodegenerative Diseases (DZNE)
    University of Bonn)

  • Victor M. Corman

    (Berlin Institute of Health
    German Center for Infection Research (DZIF))

  • Antje K. C. Echterhoff

    (German Center for Neurodegenerative Diseases (DZNE))

  • Marcel A. Müller

    (Berlin Institute of Health
    German Center for Infection Research (DZIF))

  • Anja Richter

    (Berlin Institute of Health)

  • Antonio Schmandke

    (German Center for Neurodegenerative Diseases (DZNE))

  • Marie Luisa Schmidt

    (Berlin Institute of Health
    German Center for Infection Research (DZIF))

  • Thomas H. Schmidt

    (German Center for Neurodegenerative Diseases (DZNE))

  • Folgerdiena M. Vries

    (German Center for Neurodegenerative Diseases (DZNE))

  • Christian Drosten

    (Berlin Institute of Health
    German Center for Infection Research (DZIF))

  • Monique M. B. Breteler

    (German Center for Neurodegenerative Diseases (DZNE)
    University of Bonn)

Abstract

To estimate the seroprevalence and temporal course of SARS-CoV-2 neutralizing antibodies, we embedded a multi-tiered seroprevalence survey within an ongoing community-based cohort study in Bonn, Germany. We first assessed anti-SARS-CoV-2 immunoglobulin G levels with an immunoassay, followed by confirmatory testing of borderline and positive test results with a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (PRNT). Those with a borderline or positive immunoassay result were retested after 4 to 5 months. At baseline, 4771 persons participated (88% response rate). Between April 24th and June 30th, 2020, seroprevalence was 0.97% (95% CI: 0.72−1.30) by immunoassay and 0.36% (95% CI: 0.21−0.61) when considering only those with two additional positive confirmatory tests. Importantly, about 20% of PRNT+ individuals lost their neutralizing antibodies within five months. Here, we show that neutralizing antibodies are detectable in only one third of those with a positive immunoassay result, and wane relatively quickly.

Suggested Citation

  • N. Ahmad Aziz & Victor M. Corman & Antje K. C. Echterhoff & Marcel A. Müller & Anja Richter & Antonio Schmandke & Marie Luisa Schmidt & Thomas H. Schmidt & Folgerdiena M. Vries & Christian Drosten & M, 2021. "Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22351-5
    DOI: 10.1038/s41467-021-22351-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-22351-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-021-22351-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ourania S. Kotsiou & George D. Vavougios & Dimitrios Papagiannis & Elena Matsiatsiou & Dimitra Avgeri & Evangelos C. Fradelos & Dimitra I. Siachpazidou & Garifallia Perlepe & Angeliki Miziou & Athanas, 2022. "Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave," IJERPH, MDPI, vol. 19(10), pages 1-8, May.
    2. Johannes Korth & Benjamin Wilde & Sebastian Dolff & Jasmin Frisch & Michael Jahn & Adalbert Krawczyk & Mirko Trilling & Leonie Schipper & Sebastian Cordes & Birgit Ross & Monika Lindemann & Andreas Kr, 2021. "SARS-CoV-2 Seroprevalence in Healthcare Workers in Germany: A Follow-Up Study," IJERPH, MDPI, vol. 18(9), pages 1-10, April.
    3. Felix Dewald & Martin Pirkl & Martha Paluschinski & Joachim Kühn & Carina Elsner & Bianca Schulte & Jacqueline Knüfer & Elvin Ahmadov & Maike Schlotz & Göksu Oral & Michael Bernhard & Mark Michael & M, 2023. "Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients," Nature Communications, Nature, vol. 14(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22351-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.